Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
Payal Deepak ShahAlexander C HuangGeorge X XuRobert J OrlowskiRavi K AmaravadiLynn M SchuchterPaul J ZhangJulia TchouTina MatlawskiAmanda CerviniJoanne SheaJoan GilmoreLester LledoKaren DengelAmy MarshallE John WherryGerald P LinetteAndrea BrennanVanessa E GonzalezIrina KulikovskayaSimon F LaceyGabriela PlesaCarl H JuneRobert A AndersTara C MitchellPublished in: Cancer research communications (2023)
Data evaluating CAR T therapy in patients with solid tumors are limited. This pilot clinical trial demonstrates that intravenous cMET-directed CAR T-cell therapy is safe and feasible in patients with metastatic melanoma and metastatic breast cancer, supporting the continued evaluation of cellular therapy for patients with these malignancies.
Keyphrases
- cell therapy
- metastatic breast cancer
- clinical trial
- study protocol
- phase ii
- phase iii
- stem cells
- mesenchymal stem cells
- open label
- randomized controlled trial
- electronic health record
- high dose
- big data
- double blind
- nucleic acid
- machine learning
- data analysis
- placebo controlled
- artificial intelligence
- smoking cessation